ST6GALNAC4 and acute lymphoblastic leukemia: Third, intravenous transplantation of T-ALL into immunodeficient NOD/SCID/IL2Rγ−/− (NSG) mice similarly revealed slowed progression of tumors depleted of St6galnac4. This was accompanied by a relative increase in myeloid cells (CD11b+ cells: 14.5% vs. 7.4% in control) (SI Appendix, Fig. S16 F–H).